Observational studyPloS one2015
Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients.
Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Review
- Preoperative prediction of Ki-67 expression in breast cancer using a combined radiomics model based on 18F-FDG PET/CT.Medicine · 2026Article
- Fusion of habitat analysis and deep learning on contrast-enhanced T1-weighted imaging for predicting Ki-67 status in pediatric brain tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).International journal of oncology · 2025Review
- Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.Cancers · 2023Review
- Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.Ecancermedicalscience · 2022Article
- Review
- Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.Cancers · 2021Review
- Review
- Review
- Identification of novel prognostic genes of triple-negative breast cancer using meta-analysis and weighted gene co-expressed network analysis.Annals of translational medicine · 2021Article
- Hispidulin modulates epithelial-mesenchymal transition in breast cancer cells.Oncology letters · 2021Article
- Identification of adriamycin resistance genes in breast cancer based on microarray data analysis.Translational cancer research · 2020Article
- Review
- Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.BMC cancer · 2020Article
- Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients.Journal of breast cancer · 2020Article
- Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer.Indian journal of surgical oncology · 2019Article
- E-Cadherin Downregulation is Mediated by Promoter Methylation in Canine Prostate Cancer.Frontiers in genetics · 2019Article
- Androgen receptor gene expression in primary breast cancer.NPJ breast cancer · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTNBC is an aggressive subset of breast cancer (BC) without specific target therapy.
methodsThis observational, retrospective study included 45 cases of TNBC. The aim of this study was to evaluate the expression of the AR, E-cadherin and Ki-67 in relation to histological type, time to relapse and overall survival (OS). Immunohistochemistry (IHC) was carried out on formalin-fixed paraffin-embedded tumor samples obtained from patients defined TNBC.
resultsThe AR was positive (IHC >10%) in 26.6%. E-cadherin (CDH1) expression was considered positive if the score was ≥ 2. This expression was negative in 53.3% cases. The Ki-67 index was ≥ 20% in 37.7%. Univariate analyses showed that AR, CDH1 and Ki-67 are significantly associated with OS. Multivariate analysis showed that AR and Ki-67 expression are independent variables associated with OS. The statistical analysis showed that patients with AR negative and Ki-67 positive expression have a significant correlation with poor outcome.
conclusionsOur data suggest that the combination of AR and E-cadherin expression as well as Ki-67 status might be useful prognostic markers in TNBC. Hence, these molecular determinants could play an interesting role to classify subgroups of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.